About
Accuitis is engaged in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. Our lead product is a transformational first in class treatment for Rosacea. The world-wide dermatology market is expected to grow to $22.7 billion by 2017 with the key drivers of growth being driven by innovation in chronic disease states such as psoriasis. Our compound is a first-in-class proteasome inhibitor for the treatment of rosacea and other topical skin diseases. It offers the potential to transform the value of the rosacea market through innovation to one of the largest segments in the dermatology market. Additionally the compound has promise as a therapeutic targeting skin aging, acne, and dry eye, by breaking the inflammatory cascade associated with these disease states. The combined estimated market potential for our compound is expected to exceed $500 million dollars in US sales annually.